ChromaDex (NASDAQ:CDXC) Price Target Raised to $8.00 at HC Wainwright

ChromaDex (NASDAQ:CDXC) had its price objective boosted by HC Wainwright from $6.00 to $8.00 in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS and FY2025 earnings at $0.21 EPS.

ChromaDex Stock Down 3.1 %

Shares of CDXC stock opened at $6.77 on Monday. The firm has a market cap of $517.09 million, a price-to-earnings ratio of 677.68 and a beta of 1.88. ChromaDex has a 52-week low of $1.32 and a 52-week high of $7.08. The company’s 50 day moving average is $3.77 and its 200 day moving average is $3.31.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period last year, the business posted ($0.01) EPS. Analysts anticipate that ChromaDex will post 0.02 EPS for the current fiscal year.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDXC. OneDigital Investment Advisors LLC increased its holdings in shares of ChromaDex by 5.5% during the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock valued at $217,000 after acquiring an additional 3,097 shares in the last quarter. Miracle Mile Advisors LLC purchased a new stake in ChromaDex during the 2nd quarter worth approximately $27,000. The Manufacturers Life Insurance Company acquired a new position in ChromaDex during the 2nd quarter valued at approximately $31,000. Merriman Wealth Management LLC acquired a new position in ChromaDex during the 2nd quarter valued at approximately $32,000. Finally, Lazard Asset Management LLC purchased a new position in shares of ChromaDex in the first quarter worth $43,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.